Mon, Aug 24, 2026
[Archive]
Articles In Press
Back to the articles list |
Back to browse issues page
1- Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
2- Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran ,sharafi.a@gmail.com
2- Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran ,
Abstract: (307 Views)
Background and Objectives: Glioblastoma multiform is one of the most malignant primary brain tumors, which shows poor prognosis and limited therapeutic choices. Protein tyrosine phosphatase receptor type Z1 (PTPRZ1) is overexpressed in GBM and forms a promising target of immunotherapeutic intervention.
Materials and Methods: In the current study, Fc-fusion technology was used to increase the stability and possible functional activity of the recombinant protein. The PTPRZ1 fragment was inserted into the pET28a expression vector and then transformed into E. coli BL21 (DE3) using the heat-shock method. Optimization of recombinant protein expression was performed by varying induction time (2, 4, and overnight hours), IPTG concentration (1 mM), and temperature (37°C for initial growth and induction). Protein expression was performed in the E. coli BL21 (DE3) and subsequently was confirmed using SDS-PAGE, Bradford, and western blot techniques.
Results: The SDS-PAGE analysis revealed a recombinant protein with an estimated molecular weight of about 46.3 kDa. The protein was then purified with denaturing conditions using Ni-NTA affinity chromatography. The insoluble fraction had the highest protein concentration, approximately 700 µg/mL, as determined by the Bradford assay at 595nm. Western blot analysis also confirmed the recombinant protein, with an approximate molecular weight of 46.3 kDa.
Conclusion: The current research indicates that Fc-PTPRZ1 fusion proteins could be useful for the immunotherapy of glioblastoma, but further in vivo studies are needed to assess their immunogenicity and therapeutic potential.
Materials and Methods: In the current study, Fc-fusion technology was used to increase the stability and possible functional activity of the recombinant protein. The PTPRZ1 fragment was inserted into the pET28a expression vector and then transformed into E. coli BL21 (DE3) using the heat-shock method. Optimization of recombinant protein expression was performed by varying induction time (2, 4, and overnight hours), IPTG concentration (1 mM), and temperature (37°C for initial growth and induction). Protein expression was performed in the E. coli BL21 (DE3) and subsequently was confirmed using SDS-PAGE, Bradford, and western blot techniques.
Results: The SDS-PAGE analysis revealed a recombinant protein with an estimated molecular weight of about 46.3 kDa. The protein was then purified with denaturing conditions using Ni-NTA affinity chromatography. The insoluble fraction had the highest protein concentration, approximately 700 µg/mL, as determined by the Bradford assay at 595nm. Western blot analysis also confirmed the recombinant protein, with an approximate molecular weight of 46.3 kDa.
Conclusion: The current research indicates that Fc-PTPRZ1 fusion proteins could be useful for the immunotherapy of glioblastoma, but further in vivo studies are needed to assess their immunogenicity and therapeutic potential.
Type of Study: Original Research Article |
Subject:
Life Science
Received: 2025/12/20 | Accepted: 2026/06/2
Received: 2025/12/20 | Accepted: 2026/06/2
References
1. Nagai K, Fujii M, Kitazume S. Protein tyrosine phosphatase receptor type Z in central nervous system disease. Int J Mol Sci. 2022;23(8):4414. [DOI:10.3390/ijms23084414] [PMID] [PMCID]
2. Zhang H, Wang Z, Qiao X, Wu J, Cheng C. Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study. BMC cancer. 2025;25(1):654. [DOI:10.1186/s12885-025-13979-3] [PMID] [PMCID]
3. Grzegorzewski J, Michalak M, Wołoszczuk M, Bulicz M, Majchrzak-Celińska A. Nanotherapy of glioblastoma-Where hope grows. Int J Mol Sci. 2025;26(5):1814. [DOI:10.3390/ijms26051814] [PMID] [PMCID]
4. Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P, et al. Glioblastoma: Clinical presentation, multidisciplinary management, and long-term outcomes. Cancers. 2025;17(1):146. [DOI:10.3390/cancers17010146] [PMID] [PMCID]
5. Patel V, Chavda V. Intraoperative glioblastoma surgery-current challenges and clinical trials: An update. Cancer Pathog Ther. 2024;2(04):256-67. [DOI:10.1016/j.cpt.2023.11.006] [PMID] [PMCID]
6. Cruz JVR, Batista C, Afonso BdH, Alexandre-Moreira MS, Dubois LG, Pontes B, et al. Obstacles to glioblastoma treatment two decades after temozolomide. Cancers. 2022;14(13):3203. [DOI:10.3390/cancers14133203] [PMID] [PMCID]
7. Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current immunotherapies for glioblastoma multiforme. Front Immunol. 2021;11:603911. [DOI:10.3389/fimmu.2020.603911] [PMID] [PMCID]
8. Sener U, Ruff MW, Campian JL. Immunotherapy in glioblastoma: current approaches and future perspectives. Int J Mol Sci. 2022;23(13):7046. [DOI:10.3390/ijms23137046] [PMID] [PMCID]
9. Zhao B, Wu J, Li H, Wang Y, Wang Y, Xing H, et al. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. Cell Commun. Signal. 2023;21(1):74. [DOI:10.1186/s12964-023-01098-0] [PMID] [PMCID]
10. Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. Bio Drugs. 2015;29(4):215-39. [DOI:10.1007/s40259-015-0133-6] [PMID] [PMCID]
11. Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc‐fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4(10):1015-28. [DOI:10.1002/emmm.201201379] [PMID] [PMCID]
12. Krendyukov A, Gieffers C. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019:8095-100. [DOI:10.2147/CMAR.S216675] [PMID] [PMCID]
13. El-Ghlban S, Kasai T, Shigehiro T, Yin HX, Sekhar S, Ida M, et al. Chlorotoxin‐Fc fusion inhibits release of MMP‐2 from pancreatic cancer cells. Bio Med Res Int. 2014;2014(1):152659. [DOI:10.1155/2014/152659] [PMID] [PMCID]
14. Beffinger M, Schellhammer L, Taskoparan B, Deplazes S, Salazar U, Tatari N, et al. FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. Nat Commun. 2025;16(1):4751. [DOI:10.1038/s41467-025-59971-0] [PMID] [PMCID]
15. Müller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, et al. A role for receptor tyrosine phosphataseζ in glioma cell migration. Oncogene. 2003;22(43):6661-8. [DOI:10.1038/sj.onc.1206763] [PMID]
16. Ulbricht U, Brockmann MA, Aigner A, Eckerich C, Müller S, Fillbrandt R, et al. Expression and function of the receptor protein tyrosine phosphatase ζ and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol. 2003;62(12):1265-75. [DOI:10.1093/jnen/62.12.1265] [PMID]
17. Gharbavi M, Danafar H, Amani J, Sharafi A. Immuno-informatics analysis and expression of a novel multi-domain antigen as a vaccine candidate against glioblastoma. Int Immunopharmacol. 2021;91:107265. [DOI:10.1016/j.intimp.2020.107265] [PMID] [PMCID]
18. Kruger NJ. The Bradford method for protein quantitation. The protein protocols handbook. 2009:17-24. [DOI:10.1007/978-1-59745-198-7_4]
19. Salvato I, Marchini A. Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives. Cancers. 2024;16(7):1276. [DOI:10.3390/cancers16071276] [PMID] [PMCID]
20. Frederico SC, Hancock JC, Brettschneider EE, Ratnam NM, Gilbert MR, Terabe M. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front. Oncol. 2021;11:672508. [DOI:10.3389/fonc.2021.672508] [PMID] [PMCID]
21. Fujikawa A, Sugawara H, Tanaka T, Matsumoto M, Kuboyama K, Suzuki R, et al. Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells. Sci. Rep. 2017;7(1):5609. [DOI:10.1038/s41598-017-05931-8] [PMID] [PMCID]
22. Gaits F, Li R, Ragab A, Selves J, Ragab-Thomas J, Chap H. Implication of a protein-tyrosine-phosphatase in human lung cancer. Cell Mol Biol. (Noisy-le-Grand, France). 1994;40(5):677-85.
23. Fujikawa A, Nagahira A, Sugawara H, Ishii K, Imajo S, Matsumoto M, et al. Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma. Sci Rep. 2016;6(1):20473. [DOI:10.1038/srep20473] [PMID] [PMCID]
24. Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K. RNA interference targeting protein tyrosine phosphatase ζ/receptor‐type protein tyrosine phosphatase β suppresses glioblastoma growth in vitro and in vivo. J Neurochem. 2006;98(5):1497-506. [DOI:10.1111/j.1471-4159.2006.04022.x] [PMID]
25. Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS-J, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8(1):15080. [DOI:10.1038/ncomms15080] [PMID] [PMCID]
26. Qin EY, Cooper DD, Abbott KL, Lennon J, Nagaraja S, Mackay A, et al. Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma. Cell. 2017;170(5):845-59. e19. [DOI:10.1016/j.cell.2017.07.016] [PMID] [PMCID]
27. Sørensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol. 2005;115(2):113-28. [DOI:10.1016/j.jbiotec.2004.08.004] [PMID]
28. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5:172. [DOI:10.3389/fmicb.2014.00172]
29. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology. Curr Opin Biotechnol. 2009;20(6):692-9. [DOI:10.1016/j.copbio.2009.10.010] [PMID]
30. Hirasawa S, Kitahara Y, Okamatsu Y, Fujii T, Nakayama A, Ueno S, et al. Facile and efficient chemoenzymatic semisynthesis of Fc-fusion compounds for half-life extension of pharmaceutical components. Bioconjug Chem. 2019;30(9):2323-31. [DOI:10.1021/acs.bioconjchem.9b00235] [PMID]
31. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35(2):235-54. [DOI:10.3109/07388551.2013.834293] [PMID] [PMCID]
32. Alleva DG, Delpero AR, Scully MM, Murikipudi S, Ragupathy R, Greaves EK, et al. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine. 2021;39(45):6601-13. [DOI:10.1016/j.vaccine.2021.09.077] [PMID] [PMCID]
33. Niu YX, Xu ZX, Yu LF, Lu YP, Wang Y, Wu C, et al. Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. Int Immunopharmacol. 2022;109:108783. [DOI:10.1016/j.intimp.2022.108783] [PMID]
34. Mahmud H, Kasai T, Khayrani AC, Asakura M, Oo AKK, Du J, et al. Targeting glioblastoma cells expressing CD44 with liposomes encapsulating doxorubicin and displaying chlorotoxin-IgG Fc fusion protein. Int J Mol Sci. 2018;19(3):659. [DOI:10.3390/ijms19030659] [PMID] [PMCID]
35. Huang R, Liu Y, Wang K, Wang Z, Zhang C, Zhang W, et al. High‐sensitive clinical diagnostic method for PTPRZ1‐MET and the characteristic protein structure contributing to ligand‐independent MET activation. CNS Neurosci. 2021;27(5):617-28. [DOI:10.1111/cns.13627] [PMID] [PMCID]
36. Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, et al. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncoimmunology. 2018;7(2):e1391972. [DOI:10.1080/2162402X.2017.1391972] [PMID] [PMCID]
37. Yu MW, Quail DF. Immunotherapy for glioblastoma: current progress and challenges. Front Immunol. 2021;12:676301. [DOI:10.3389/fimmu.2021.676301] [PMID] [PMCID]
38. Kong X, Ou S, Wei Z, Ye X, Chen S, Shi X, et al. Transforming the "cold" tumors to "hot" tumors: strategies for immune activation. Biochem Pharmacol. 2025:117194. [DOI:10.1016/j.bcp.2025.117194] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Zanjan University of Medical Sciences is licensed under CC BY-NC 4.0
